Endothelial nitric oxide synthase (eNOS) variants in cardiovascular disease: Pharmacogenomic implications

Indian Journal of Medical Research

Volumn 133, Issue 5, 2011, Pages 464-466

  Bhanoori, Manjula ^a  

^a OSMANIA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED RELAXING FACTOR; NITRIC OXIDE;

CARDIOVASCULAR DISEASE; DRUG METABOLISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ETHNIC GROUP; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN GENOME PROJECT; HYPERLIPIDEMIA; HYPERTENSION; NOTE; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; CHROMOSOME 7; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; INDIA; MISSENSE MUTATION; PHARMACOGENETICS;

CARDIOVASCULAR DISEASES; CHROMOSOMES, HUMAN, PAIR 7; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INDIA; MUTATION, MISSENSE; NITRIC OXIDE SYNTHASE TYPE III; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79958024035     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Note

References (33)

1. Cavalli-Sforza LL. The Human Genome Diversity Project: past, present and future. Nat Rev Genet 2005; 6: 333-40.
2. Crawford DC, Akey DT, Nickerson DA. The patterns of natural variation in human genes. Annu Rev Genomics Hum Genet 2005; 6: 287-312.
3. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-7.
4. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001; 293: 489-93.
5. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008; 118: 1590-605.
6. WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-78.
7. Chakravati A. To a future of genetic medicine. Nature 2000; 409: 822-3.
8. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003; 348: 1170-5.
9. Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discovery 2002; 1: 300-8.
10. Sim DS, Lieu H, Andre P. Biomarkers and bioassays for cardiovascular diseases: Present and future. Biomark Insights 2008; 3: 293-302.
11. Chugh SS, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M, et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 2008; 51: 213-28.
12. Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004; 4: 151-60.
13. Johnson JA. Ethnic differences in cardiovascular drug response: rotential contribution of pharmacogenetics. Circulation 2008; 118: 1383-93.
14. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
15. Smith O. Nobel Prize for NO research. Nat Med 1998; 4: 1215.
16. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
17. Dudzinski DM, Igarashi J, Greif DM, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006; 46: 235-76.
18. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-42.
19. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-95.
20. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol 2006; 164: 921-35.
21. Hingorani AD. Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French Lecture 2000. Atherosclerosis 2001; 154: 521-7.
22. Zintzaras E, Kitsios G, Stefanidis I. Endothelial NO synthase gene polymorphisms and hypertension: a meta-analysis. Hypertension 2006; 48: 700-10.
23. Cardon LR, Bell JL. Association study designs for complex diseases. Nat Rev Genet 2001; 2: 91-9.
24. Shankarishan P, Borah PK, Ahmed G, Mahanta J. Prevalence of endothelial nitric oxide synthase (eNOS) gene exon 7 Glu298Asp variant in North Eastern India. Indian J Med Res 2011; 133: 487-91.
25. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000; 97: 2832-5.
26. Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC. Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)!Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001; 276: 26674-9.
27. Metzger IF, Sertorio JT, Tanus-Santos JE. Modulation of nitric oxide formation by endothelial nitric oxide synthase gene halotypes. Free Radic Biol Med 2007; 43: 987-92.
28. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 2001; 11: 719-25.
29. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002; 90: 21-8.
30. Leeson CP, Hingorani AD, Mullen MJ, Jeerooburkhan N, Kattenhorn M, Cole TJ, et al. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 2002; 90: 1153-8.
31. Lacchini R, Silva PS, Tanus-Santos JE. A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins. Basic Clin Pharmacol Toxicol 2010; 106: 357-61.
32. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16: 834-9.
33. Cooke GE, Doshi A, Binkley PF Endothelial nitric oxide synthase gene: prospects for treatment of heart disease. Pharmacogenomics 2007; 8: 1723-34.